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Translational relevance: Here we firstly developed an optimized approach to robustly wash 
off immunofluorescence signals and perform multiple rounds of fluorescence in situ 
hybridization analysis on the same cells. This facilitates the genomic analysis and 
confirmation of circulating tumor cells (CTCs), valuable for cancer diagnosis, prognosis and 
progression monitoring. Prostate cancer patients with advanced clinical features showed an 
increasing number of epithelial/EMTing/mesenchymal CTCs. The presence of metastasis was 
efficiently predicted by a combined risk score based on both serum PSA level and EMTing 
CTC count. These analyses greatly enhance our ability to investigate metastasis process and 
to predict/monitor cancer progression. The most important novel finding was the association 
of circulating megakaryocytes with good prognosis. In combination with mesenchymal CTC 
count, they showed great cancer prognosis potential. The identification of circulating 
megakaryocytes and their association with cancer prognosis potentially opens a new revenue 





Purpose: To develop an approach for the investigation of different subtypes of circulating 
tumor cells (CTCs) and other cells to evaluate their potential prognostic value of prostate 
cancer. 
Experimental Design: Malignancy of CTCs undergoing epithelial to mesenchymal transition 
(EMT) was confirmed by repeated Fluorescence in situ hybridization. Subgroups of CTCs in 
81 patients with prostate cancer (43 castration resistant and 38 untreated localized) were 
correlated to disease aggressiveness parameters. Area under curve analysis was applied to 
compare the performance for metastasis prediction between serum PSA level alone and a 
combined risk score using both PSA and EMTing CTC count. Circulating megakaryocytes 
and cancer patient survival association was performed using Cox model.  
Results: The majority of vimentin(VIM)+/CD45- cells were malignant with genomic 
alterations in several genomic regions. The number of cytokeratin(CK)-/VIM+/CD45- CTCs 
correlated with disease burden, tumor aggressiveness and poorer survival. Meanwhile, 
CK+/VIM+/CD45- CTCs were associated with metastases better than other subtypes of 
CTCs in these limited samples. Combination of PSA level and the number of 
CK+/VIM+/CD45- CTCs enhanced the prediction of cancer metastases (AUC 0.921, 95%CI: 
0.858-0.985). The number of circulating megakaryocytes was potentially associated with 
good patient survival in advanced prostate cancer (HR:0.849, 95%CI:0.628-1.146, per cell 
increase) and the difference between the number of mesenchymal CTCs and megakaryocytes 
strongly correlated to poor survival (HR:10.17, 95%CI:2.164-47.789, if score 2.0).  
Conclusions: This CTC analysis approach and the potential association of megakaryocytes 
with cancer prognosis may greatly enhance our ability to investigate the cancer metastasis 
process and to predict/monitor cancer progression. 
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Introduction 
Cancer cells evolve during disease progression and in response to treatment (1), influencing 
their sensitivity to treatment. Circulating tumor cells (CTCs) are considered to be the seeds of 
metastases (2) and, at the same time, a source of information on tumor tissue that can be 
acquired through a simple blood sample. Even before a metastatic tumor is clinically evident, 
it has been reported that a large number of CTCs already exist in the circulation (3,4). This 
provides a more accessible ‘liquid biopsy’ than tumor tissue biopsies to predict/monitor 
disease progression and therapy response at both cellular and molecular level. However, 
current CTC analysis mainly focused on cells expressing epithelial phenotype-specific 
markers (2). In fact, activation of epithelial-mesenchymal transition (EMT) is a key process 
in cancer metastasis (5) and an important factor in promoting invasiveness of cancer cells and 
their resistance to therapy (6). Both down-regulation of epithelial markers, such as epithelial 
cell adhesion molecule (EpCAM), cytokeratin (CK), and E-cadherin, and up-regulation of 
mesenchymal markers, such as vimentin (VIM), and N-cadherin, have been described (7,8). 
Hence, CTCs undergoing EMT as part of the metastatic process may be missed when isolated 
based on their epithelial characteristics only. To address this challenge, we have optimized a 
novel epitope independent CTC isolation system, Parsortix, to capture CTCs based on the 
much larger size and less deformability nature of tumor cells compared to normal blood cells 
(9). The efficiency of Parsortix in capturing CTCs has been independently validated by other 
research groups in comparison to CellSearch
® 
in patients with small cell lung cancer (10), and 
other types of cancer including breast, colon and lung (11). Here we explored its clinical 
application in prostate cancer prognosis and disease state monitoring.  
Prostate cancer is the most common cancer in Western men (12,13). Current criteria for 
risk stratification of newly diagnosed prostate cancer are mainly based on clinical features, 
including serum prostate specific antigen (PSA), clinical stage, and biopsy/surgical specimen 
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Gleason score (GS)(14). However, these factors are not sufficient to discriminate between 
patients with indolent and aggressive disease. Furthermore, when metastatic disease 
progresses to castration-resistant prostate cancer (CRPC), the established PSA test is not 
satisfactory for disease prognosis and monitoring. These current clinical unmet needs urge us 
to identify novel biomarkers that can monitor disease status precisely, accessibly and in real 
time. Therefore, we investigated the potential of analyzing CTCs with both epithelial and 
mesenchymal features for cancer prognosis using Parsortix
™
 system in prostate cancer as a 
disease model. We developed a novel technique to perform five rounds of fluorescence in situ 
hybridization (FISH) on the same slides after immunofluorescence staining. Using this 
technique, we simultaneously identified the epithelial and mesenchymal cell features and 
multiple genomic alterations, confirming the malignancy of circulating cells with 
mesenchymal phenotype. We also demonstrated the correlation of CTCs with advanced 
disease features. Unexpectedly, we discovered that an increase of circulating megakaryocytes 
had the trend to be correlated with good prognosis in patients with progressive disease and 
the combination of CTC and megakaryocyte count may effectively predict survival in 
advanced disease.  
Materials and Methods 
Patients and blood samples 
A total of 81 patients with written consent were recruited from December 2014 in St 
Bartholomew's Hospital, Barts Health NHS, London, UK, comprising 38 with untreated 
localized prostate cancer, and 43 with progressive CRPC (40 with metastasis) ready to 
commence an alternative treatment. The clinical information is summarized in Table 1 and 
details of sample collection and clinical information were shown in Supplementary Data and 
Table S1. Blood specimens from 24 healthy male donors were collected with signed Ethics 
 8 
committee approved consent forms. 7.5mL of whole blood was donated from each participant 
for CTC enumeration. Use of blood samples from patients and healthy donors in this study 
was approved by National Research Ethics Service committee London City & East with a 
Research Ethics Committee reference of 09/H0704/4+5. 
CTC isolation and enumeration 
Isolation of CTCs from whole blood using a size- and deformability-based system Parsortix 
was performed as previously described (9). Sample harvest and the process of 
immunostaining are detailed in Supplementary Materials and Methods. Different DAPI+ 
populations of cells were recorded, including CK+/VIM-/CD45-, CK+/VIM+/CD45-, and 
CK-/VIM+/CD45-. 
FISH after immunofluorescence analysis 
Immunofluorescence signals were washed in a stripping buffer (containing 2% SDS, 
0.0625M Tris-HCl pH6.8 and 0.8% β-mercaptoethanol) at 50°C for 20 minutes, followed by 
washing three times in PBS for 5 minutes. Details of FISH probe and multiple FISH 
procedure are indicated in Supplementary Materials and Methods. Ten FISH probes for nine 
commonly altered genes/genomic regions in prostate cancer, including 6q16, NKX3.1, C-
MYC, PTEN, CCND1, RB1, 16q22.1, ERG and AR were used for CTC analysis. The copy 
number of each FISH probe was counted in CK+/VIM-/CD45-, CK+/VIM+/CD45-, CK-
/VIM+/CD45- and CK-/VIM-/CD45- cells. The copy number of lymphocytes from the 
prostate cancer patients and healthy donors were used to calculate the baseline for each 
genetic change. FISH signals from >100 lymphocytes were counted in each sample.  
Statistics 
Unless specifically noted, Wilcoxon rank-sum test was applied to assess the equality of CTCs 
between subgroups based on CTC-score as well as different clinical features, such as 
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metastasis, primary GS, and risk classification in localized disease. Data shown was as 
median (interquartile range [IQR]). Spearman’s rank correlation was used to assess the 
association between CTC counts and concurrent PSA level.  Bivariate logistic regression was 
performed with PSA and EMTing CTC counts as predictors for imaging detected metastasis 
(yes, no). A combined risk score (CRS) was computed as the linear predictor of the fitted 
bivariate logistic model with PSA and EMTing CTC count as only predictors (as CRS = a* 
PSA + b * EMTing CTC count, where the values of ‘a’ and ‘b’ are the estimated log odds 
ratios). Receiver operating characteristic (ROC) curve analysis was used to test the ability of 
different subtypes of CTCs as well as CRS to distinguish patients with metastasis. Optimal 
cut-off point was calculated with an optimal corrected classified value to provide best 
available sensitivity and specificity. Rocgold function was used to independently test the 
equality of the ROC area of each method against the PSA as a standard curve. The combined 
mesenchymal CTC and megakaryocyte score (CMS) was calculated as: 
𝑚𝑒𝑠𝑒𝑛𝑐ℎ𝑦𝑚𝑎𝑙 𝐶𝑇𝐶 𝑐𝑜𝑢𝑛𝑡 − 𝑚𝑒𝑔𝑎𝑘𝑎𝑟𝑦𝑜𝑐𝑡𝑒 𝑐𝑜𝑢𝑛𝑡
𝑚𝑒𝑔𝑎𝑘𝑎𝑟𝑦𝑜𝑐𝑡𝑒 𝑐𝑜𝑢𝑛𝑡
 
Due to possible absence of megakaryocytes detected in patients, megakaryocyte count equal 
to 0 was recorded as 1 for this score calculation. To determine the factors that predict survival 
time, variables considered as potential predictors were selected for univariate analyses using 
Cox model. The hazard ratio associated with each biomarker was derived from the Cox 
model as an increase in the hazard per unit increase in biomarker. Due to the small sample 
size, p value for the hazard ratio were further adjusted by false discovery rate using 
Benjamini & Hochberg’s adjustment method (15). Survival curves were generated using the 
Kaplan-Meier method and compared using the log-rank test. All statistical tests were two 
sided and p-values less than 0.05 (including multiple test adjustment where relevant) were 
considered as statistically significant. Bonferroni correction test was performed to modify p 
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values for multiple tests through dividing the critical p value by the number of comparisons 
being made. Statistical analyses were performed using Stata 13.0. 
 
Results  
Detection of circulating cells with epithelial and mesenchymal features 
Using our optimized CTC isolation and detection method (9), we analyzed blood samples 
from 81 prostate cancer patients (Table 1 and S1) to identify CK+/VIM-/CD45-, 
CK+/VIM+/CD45- and CK-/VIM+/CD45- circulating cells (Fig. 1A). All three types of cells 
have been detected at high frequencies both in the blood of CRPC and localized cancer 
patients and they are higher in CRPC patients than those in untreated patients (Table 1). Of 
81 patients studied, 15 (19%) patients had no detectable CK+/CD45- cells but detectable CK-
/VIM+/CD45- circulating cells.  
Genetic evidence that CK-/VIM+/CD45- circulating cells are malignant cells with 
genomic alterations 
To confirm the malignant feature of CK-/VIM+/CD45- circulating cells by detecting multiple 
genomic alterations, we developed a technology for repeated multiple rounds of FISH 
analysis after immunofluorescence staining, and applied it on the CTC samples. This post- 
immunofluorescence multiple FISH analysis technique was developed using slides with 
lymphocytes spiked with PC3 cells, in which we removed the immunofluorescence signals 
completely by the stripping buffer, but not by 2XSSC buffer, fix solution or proteinase K 
digestion. The length of poly-lysine slide coating time was optimized to 45 minutes to best 
preserve cells for downstream repeated FISH analysis after signal striping. Less coating time 
frequently resulted in damaged or lost cells after signal striping. Using these optimized 
conditions, we detected clear nuclear morphology and FISH signals in up to the fifth round of 
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FISH on cells after immunofluorescence (Fig. S1). In the leucocytes from the healthy donors, 
the average false positive rates for the probes range from 0.7%-7.1% (Table S2). 
The multiple FISH technique was then successfully applied to 11 prostate cancer CTC 
cases for five rounds of FISH (Fig. 1B) and one case for two rounds due to strong florescence 
background, to investigate the genomic alterations of nine genomic regions, including 
chromosomal copy number changes and/or rearrangements. In the leucocytes from three 
randomly selected patients, the average false positive rates for the probes range from 1.5%-
7.8% (Table S2). In CTCs from an individual, each of the genomic changes was only 
detected in a proportion of cells, indicating genomic heterogeneity. In the limited number of 
cases and limited number of CTCs in each case, no obvious genomic change patterns specific 
to a subgroup of epithelial or mesenchymal CTCs were observed. Changes of more than 30% 
of the genomic regions were detected in 68% of CK+/VIM-/CD45- cells, 57% of 
CK+/VIM+/CD45- cells and 54% of CK-/VIM+/CD45- cells, but only detected in 3.7% of 
CK-/VIM-/CD45+ leucocytes and 7.8% of CK-/VIM-/CD45- cells (Table S3). The similar 
rate of genetic changes in the CK+/VIM-/CD45-, CK+/VIM+/CD45- and CK-/VIM+/CD45- 
circulating cells indicates that the majority of CK-/VIM+/CD45- cells were CTCs. While it is 
possible that small proportions of the above three circulating cell categories are of non-
malignant origin, we considered all CK+/VIM-/CD45-, CK+/VIM+/CD45- and CK-
/VIM+/CD45- cells for the correlation analysis between CTC numbers and clinical features, 
and categorized them as epithelial, EMTing or mesenchymal CTCs, respectively. When 
classifying cases as positive or negative for CTCs, the number of CK+/VIM-/CD45-, 
CK+/VIM+/CD45- and CK-/VIM+/CD45- circulating cells found in non-cancer healthy 
control cases were considered. 
Association of CTC positivity with advanced clinical features in localized and metastatic 
prostate cancer  
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Analyzing blood samples from 24 healthy male donors, we detected one, two and three CK-
/VIM+/CD45- cells in three, two and two samples, respectively, and none in the remaining 17 
samples (median 0, range 0 to 3 cells per 7.5 mL), and complete absence of CK+/VIM-
/CD45- or CK+/VIM+/CD45- circulating cells. Consequently we defined positive CTC cases 
as those showing any CK+/VIM-/CD45-, any CK+/VIM+/CD45-, and/or >3 CK-
/VIM+/CD45- cells to prevent potential false positive, although a better definition may be 
worked out from future large cohort studies. Based on these criteria, 24 of 38 patients with 
untreated localized disease (63%) and 41 of 43 CRPC patients (95%) scored positive for 
CTCs. Excluding mesenchymal CTCs reduced CTC positivity to 20 (53%) and 38 (88%) in 
these two groups of patients respectively. In all 81 patients, high serum PSA level, high GS 
and metastatic status were significantly correlated with CTC-score positive patients. In the 38 
untreated localized diseases, CTC-score positive cases have a trend to be associated with high 
risk classification based on National Comprehensive Cancer Network (NCCN) guideline 
version 1, 2016 (16), which should be further validated in a large sample cohort (Table S4).  
Association of subgroups of CTCs with serum PSA level, primary biopsy GS and the 
risk of localized tumor 
We further analyzed the relationship of different sub-populations of CTCs to PSA level, 
primary GS and the risk of localized cancer. While all three sub-populations of CTC numbers 
were significantly correlated to serum PSA levels (Spearman’s ϱ = 0.28, 0.26, and 0.36, and p 
= 0.01, 0.019 and 0.0009 respectively for CK+/VIM-/CD45-, CK+/VIM+/CD45- and CK-
/VIM+/CD45- CTCs), the mesenchymal type had the most significant association (Fig. 2A). 
As expected, the total number of CTCs had an even more significant correlation (Spearman’s 
ϱ = 0.49, p < 0.0001) due to the greater number of events included for analysis. Due to the 
multiple tests for analysis, Bonferroni correction test was performed to modify the significant 
p values. After adjustment, mesenchymal CTC alone but not epithelial and EMTing CTC 
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alone reached statistical significance. Traditional CTCs (combination of epithelial and 
EMTing CTC) had a significant correlation.  
Higher CTC count was also detected in patients with higher GS of primary tumor 
regardless of therapies received and mesenchymal CTCs had the most significant association 
(p = 0.001). When total CTCs were included for analysis, a stronger association was observed 
(p = 0.0001) (Fig. 2B, Table S5). After multiple test correction, both epithelial and 
mesenchymal subtypes of CTCs alone were correlated with higher GS.  
When the 38 untreated patients with localized disease were divided into 
low/intermediate and high risk groups based on NCCN guideline, the number of each subtype 
of CTCs was higher in high risk group compared to low/intermediate group (Fig. 2C, Table 
S5). After adjustment for multiple tests, EMTing CTCs and the traditional CTCs (epithelial 
and EMTing CTCs) still remained statistical significance. 
EMTing CTC number was significantly associated with the presence of metastasis  
When we correlated the numbers of different sub-populations of CTCs to cancer metastasis, 
the presence of metastases was significantly associated with higher number of any type of 
CTCs and the association with EMTing CTCs was most significant (p = 0.0001), which was 
similar in significance when considering total CTCs (Fig. 2D, Table S5). Each subtype of 
CTCs alone achieved a statistical significance after p value adjustment for multiple tests. 
When a ROC curve was applied to explore the role of CTCs in metastases prediction in 
comparison with PSA, EMTing CTC count (with an optimal cutoff point at ≥ 2 cells) had the 
highest area under the ROC curve (AUC) score (0.755, 95%CI: 0.654-0.856) of all types of 
CTCs. Although the efficiency was lower than PSA (AUC =0.823, 95%CI: 0.720-0.927, with 
an optimal cutoff point at ≥ 23 ng/mL)(Table S6), when EMTing CTC count and PSA were 
combined to create a CRS (as CRS = 0.012 * PSA + 0.115 * EMTing CTC count), the CRS 
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(AUC = 0.921, 95%CI: 0.858-0.985) was a significantly (p = 0.03) better predictor of 
metastasis than PSA score alone (Fig. 2E). The increased performance of the CRS for 
metastasis prediction compared to PSA at different sensitivity and specificity level are 
presented in Table S7. Box plots of CRS in patients with/without metastasis are shown in Fig. 
S2A. 
Mesenchymal CTC count is potentially associated with poor survival 
Survival analysis was performed in the 40 metastatic CRPC (mCRPC) patients with a median 
follow-up time of 11.8 months (range 0.7-19.7 months), of which 11 (27.5%) had died. 
Median follow-up time for patients still alive at endpoint was 13.3 months (range 4.1-19.7 
months). Table 2 shows the association between potential risk factors and survival derived 
from Cox model with adjusted p value using Benjamini & Hochberg’s method (15). High 
PSA level (p = 0.015), high serum ALP level (p = 0.015), and high serum LDH level (p = 
0.040) were found to be associated with increased risk of death in univariate analyses. None 
of the subtypes of CTCs had a significant association in this small cohort. However, when a 
cut-off was selected to optimally demonstrate the significance (Fig. S3), patients with 
mesenchymal CTCs (≥ 5 cells) had an HR of 8.458 (95%CI: 1.815-39.411, p = 0.001). 
Patients with epithelial (≥ 3 cells), EMTing (≥ 2 cells) and total CK+ (≥ 6 cells) CTCs had an 
HR of 2.765 (95%CI: 0.732-10.438), 1.858 (95%CI: 0.491-7.033), and 1.537 (95%CI: 0.449-
5.261), respectively, none reached statistical significance.  
The presence of circulating megakaryocytes was associated with better survival  
Unexpectedly, we found a rare population of cells in the harvest samples, with big nuclei 
(larger than both lymphocytes and most CTCs) of strong DAPI staining, but negative for CK, 
VIM and CD45 (called BigNeg below)(Fig. 3A). Due to the strong DAPI staining and larger 
size of nuclei, such cells were easily identified from other cells with DAPI staining alone 
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(Fig. 3B). Through the absence of CK, VIM and CD45 staining, it was possible to exclude 
CTCs. FISH analysis for these cells showed 100% polyploidy and most (61.9%) of them had 
more than ten copies of the genome in each cell (Fig. 3C), suggesting a special type of cells, 
distinct to lymphocytes or CTCs. The mean nuclear diameter of BigNeg cells was 17.5 ± 4.9 
µm (range: 10 – 32 µm), while the mean nuclear diameter for lymphocytes was 6.5 ± 0.8 µm 
(range: 4 – 8 µm). No overlapping in nuclear size was observed between these two categories 
(Fig. 3D). Therefore, BigNeg cells were distinguishable from other cells by means of 
immunostaining and size measurement using the following criteria: cells with a strong DAPI 
stained nucleus ≥ 10 µm in size and negative for CD45, CK, and VIM staining. Using these 
criteria, such cells were counted in all 81 blood samples. The numbers were variable and 
lower in mCRPC patients who died during follow-up (median 1 cell/7.5 mL, IQR: 2-1 
cells/7.5mL) than those mCRPC patients still alive (median 2 cells/7.5 mL, IQR: 4-1 cells/7.5 
mL) and also than patients with untreated localized disease (median 2 cells/7.5 mL, IQR: 
4.25-0 cells/7.5 mL), though none of the differences reached significance (p value of 0.18 and 
0.33, respectively). In the 40 mCRPC patients, high BigNeg cell count had a trend to be 
associated with better survival (HR: 0.849, 95%CI: 0.628-1.146, adjusted p = 0.31, Table 2). 
When a cut-off was selected, patients with BigNeg (≥ 3 cells) had an HR of 0.144 (95% CI: 
0.018-1.129, p = 0.02). The estimated survival rates were significantly higher in those with ≥ 
3 BigNeg cells by Kaplan-Meier curve (p = 0.03, Fig. 4A). Based on previous results that 
high mesenchymal CTC counts generally represent more aggressive tumors and are 
associated with a higher risk for death, we hypothesize that the difference between the 
number of mesenchymal CTCs and BigNeg cells may further enhance the ability to predict 
survival. Using the formula (Mesenchymal CTC count – BigNeg cell count)/BigNeg cell 
count as detailed in the method and a univariate Cox model for survival analysis, the HR for 
per unit increase of the score is 1.282 (95%CI: 1.097-1.499, adjusted p = 0.015) (Table 2). 
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When a cut-off was selected, patients with CMS (≥ 2.0) had an HR of 10.170 (95% CI: 
2.164-47.789, p = 0.0005) and by Kaplan-Meier survival analysis, a CMS 2.0 cut off most 
significantly separated different survival groups (p = 0.0003, Fig. 4B).  
In blood samples from the 24 healthy donors, the median number of BigNeg cells was 1 
cell/7.5 mL (range: 0-15, IQR: 2.5-0, Fig. S2B), which was slightly lower than that in the 38 
patients with untreated localized disease (median: 2, range: 0-20, IQR: 4.25-0, Fig. S2B) (p = 
0.19) and marginally significantly lower than that in 43 CRPC patients (median: 2, range: 0-
23, IQR: 3-1, Fig. S2B) (p = 0.078). 
Finally, we characterized the BigNeg cells. Their consistent hyperploidy revealed by 
FISH analysis highly suggested a potential megakaryocyte-like origin. We established the 
megakaryocytes immunofluorescence analysis method by detecting CD34 and CD41 
expression in megakaryocytes induced by phorbol myristate acetate from K562 cells (Fig. 
4C). All BigNeg cells were CD34 positive with 92% (101/110) CD41 positive, confirming 
them as a specific group of megakaryocytes (Fig. 4D). CD45+ lymphocytes, epithelial CTCs, 
EMTing CTCs, and mesenchymal CTCs were all negative for CD34 and CD41. 
Discussion  
We have previously shown that CD45 negative cells with both epithelial and mesenchymal 
features can be detected in prostate cancer patients using Parsortix
™ 
(9). Here, we developed 
a repeated FISH analysis approach following immunofluorescence analysis on the same slide 
to investigate multiple genomic regions for alterations and, consequently, establish the 
malignancy of VIM+/CD45- cell populations, which were associated with disease burden and 
poor prognosis and have the potential to serve as an additional marker to traditional epithelial 
CTCs for clinical application. As EMT is a critical step for cancer metastasis, analyzing EMT 
CTCs has great potential for cancer prognosis and progression monitoring (7,17). Several 
non-EpCAM based CTC isolation platforms have been developed to analyze CTCs with 
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EMT, such as ISET (18,19) and Vitatex CAM platform (20). CTCs with ongoing EMT or 
completely changed into mesenchymal features have been identified and their biological and 
genetic difference from CellSearch captured CTCs have been revealed.  To our knowledge, 
the present study is the first genetic investigation of EMT CTCs using repeated FISH and the 
first investigation of potential prognostic value of EMT CTCs in prostate cancer. 
Repeated FISH analysis of CTCs generates genomic alteration information for multiple 
genomic regions in single cells, enabling the confirmation of the malignant genomic feature 
of suspicious CTCs, investigation of the heterogeneity of cancer cells by analyzing the 
differences in genomic alterations between individual cells and correlation of genomic 
alterations with cellular features and different types of CTCs to understand mechanisms of 
metastases. FISH analysis performed on cells analyzed by immunostaining (21-24) have been 
previously performed by using traditional fixation with ethanol or methanol mixed with 
acetic acid (24) and treatment with pepsin (21) to remove immunofluorescence signals. 
However, based on our experience, it was difficult to achieve complete removal of previous 
immunofluorescence signals using these pre-treatments and the leftover fluorescence signals 
often interfered with FISH signal interpretation. Our stripping buffer method, robustly 
removing immunofluorescence signals completely without damaging cell morphology, 
facilitates the analysis of multiple genomic alterations on the same cells after 
immunofluorescence, which increases the chance to detect genomic alterations in most CTCs 
to confirm their malignancy nature. A panel of genes is better than a single gene or genetic 
change for cancer prognosis (25). Multiple genomic region analysis also makes it possible to 
combine a number of genomic changes for the development of CTC-based genetic prognostic 
biomarkers. However, in this study, FISH was primarily used to confirm the malignancy of 
EMT CTCs. We observed a high frequency of alterations in CTCs in the genomic regions 
investigated, suggesting that extensive genomic alterations occur in CTCs at the stage of 
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cancer metastasis. This is consistent with a previous report that metastatic prostate cancer has 
more genomic alterations than primary tumor (26). Our results also showed that genomic 
heterogeneity exists in prostate cancer CTCs. 
In this study, we demonstrated the association of CTC number with GS and the 
aggressiveness of localized disease, which have not been reported previously. Association of 
detection of ≥ 5 traditional CellSearch
®
 isolated CTCs/7.5mL with poor prognosis in patients 
with advanced prostate cancer was initially reported around a decade ago (27-29) and have 
been recently further validated in several large-scaled clinical trials (30-33). In our small 
patient cohort, we observed the associations of ≥ 3 epithelial CTCs (CK+/VIM-/CD45-), ≥ 2 
EMTing CTCs (CK+/VIM+/CD45-), and ≥ 6 traditional CTCs (combination of epithelial and 
EMTing type) with advanced clinical features, CRPC development and poorer survival, 
which is consistent with these previous reports analyzing epithelial CTCs. By analyzing 
mesenchymal CTCs, we detected an increase of CTC positive cases in both CRPC and 
localized diseases. Of interest, high baseline mesenchymal CTC count (≥ 5 cells/7.5mL) 
before an alternative treatment in CRPC patients was better associated with poorer survival 
than the traditional CK+ CTCs in our cohort, which warrants further investigation. Moreover, 
mesenchymal CTCs associated with PSA level and GS better than epithelial CTCs and 
EMTing CTCs were most significantly correlated to cancer metastasis. All these data indicate 
a potential better prognostic value of mesenchymal than epithelial CTCs in prostate cancer. 
As the number of patients in this study is still small, these associations should be validated in 
large cohorts of samples. EMT has been increasingly recognized for its role in tumor cell 
invasion, metastatic dissemination and acquisition of therapeutic resistance (6). Loss of 
epithelial markers, such as E-cadherin, and gain of mesenchymal markers, such as VIM and 
N-cadherin, have been proven to be associated with more invasive phenotype or higher GS in 
prostate cancer cells (34,35). EMTing CTCs were most significantly associated with both 
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high-risk localized disease and metastasis, suggesting that these cells under active EMT 
process are potential indicators for cancer aggressive invasion and metastasis. Taken together, 
compared to traditional CK+ CTCs, CTCs undergoing or undergone EMT provided more 
information about disease burden and intrinsic tumor biology.  
Radionuclide bone-scan and computed tomography, the current gold standard 
procedures to detect metastatic sites, are costly, time-consuming and expose patients to 
radiation. Patients who are unlikely to have metastasis are better off avoiding these costly and 
potentially harmful procedures. PSA level has been used to predict bone metastases and 
select patients for bone scans (16). While our data also showed a strong association between 
PSA and metastasis and none of the CTC analyses taken alone outperformed PSA for 
metastatic correlation, a CRS based on both PSA level and EMTing CTC count, significantly 
improved the metastasis prediction accuracy compared to PSA alone. This suggests that 
although PSA level correlates with CTC count, they are independent factors contributing to 
cancer metastasis, potentially by representing different aspects of tumor biology. Large-scale 
trials are warranted to confirm this superior metastasis prediction model. 
The most striking finding is the unexpected discovery of increased circulating 
megakaryocytes in cancer patients and its association with the survival of CRPC patients. As 
the nuclei of megakaryocytes are big and with strong DAPI staining, they can be easily 
identified during CTC analysis. A group of large hyperploid cells with no detectable 
biomarkers (including epithelial and hepatocellular cancer specific markers) have also been 
reported recently (36). As the authors did not include any mesenchymal markers, they 
considered all these cells as CTCs with EMT. Based on our study, these cells might be a 
mixture of mesenchymal CTCs and circulating megakaryocytes. Megakaryocytes have also 
been identified in a previous CTC study of prostate cancer, but the investigators exclude them 
for further analysis (23). Taking advantage of the size and/or deformability based CTC 
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isolation platform, for example Parsortix™ here, such cells can be captured with high 
efficiency for cancer prognosis analysis. With the development of multiple treatment 
approaches for CRPC patients, real-time prognostic and therapeutic response predictive 
biomarkers are critical for stratified patient management. However, currently only CellSearch 
based CTC analysis, which mainly detects cells with epithelial features, is approved by FDA 
for CRPC patient survival prediction (2). Here we not only showed that mesenchymal CTCs 
has the potential to be better associated with patient survival than CTCs with epithelial 
features, but also found that the combination of mesenchymal CTC and megakaryocyte 
counts has a great power to predict CRPC patient survival, with 1.28-fold risk of death per 
unit increase of the CMS and 10-fold risk for patients with a score ≥ 2.0.  
In addition to the bone marrow and the spleen, megakaryocytes have also been detected 
at very low numbers in circulation (37,38). CD34 expresses in hematopoietic stem cells and 
megakaryocyte progenitor cells, which are all diploidy cells (39). Its expression can also be 
seen on mature-appearing megakaryocytes in reactive and disorders of bone marrows (40). 
CD41 is a megakaryocytic lineage specific marker, expressing neither in endothelial cells nor 
monocytes (39,41,42). The circulating megakaryocytes detected in our study with high DNA 
content and consistent expression of CD34, represent a specific and potentially abnormal type 
of megakaryocytes, in which endonuclear DNA replication is active but the CD34 expression 
is not switched off, hence premature high DNA content megakaryocytes without apparent 
lobulated nuclei. This is consistent to the finding of CD34 expression in mature-
appearing megakaryocytes in reactive and disorders of bone marrows (40) and increased 
ploidization of megakaryocytes have been reported in patients with metastatic tumors (43). 
Platelets, which are released from megakaryocytes in bone marrow has recently been 
recognized to play an important role in cancer metastasis (44,45) and the gene expression 
profile of platelets has been shown to efficiently distinguish individuals with or without 
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cancers (46). Platelet counts have also been investigated for cancer prognosis and the data are 
still conflict (47). In this study, there was no correlation of the number of platelets with either 
circulating megakaryocytes or cancer prognosis.  
The association of high number of megakaryocytes with a good survival of CRPC 
patients suggests an anti-tumor effect of megakaryocytes. To support this, megakaryocytes 
have been reported to increase their number in response to cancer bone metastasis and inhibit 
prostate and breast cancer cell growth both in vitro and in vivo (48-50). While the prognostic 
value and biological functions of megakaryocytes in cancer development and progression 
need to be further investigated, models that analyze the number difference between CTCs and 
megakaryocytes should be developed to make an efficient biomarker for survival prediction 
for patients with mCRPCs and potentially for other cancers as well. With further validation 
and cut off optimization in large sample cohorts, this study has potential to be translated into 
clinical use, for patients not only with prostate cancer but also a range of other human 
malignancies. 
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Table 1. Summary of clinical characteristics and CTC count for all patients 
 All patients, 
n = 81 
Patient with untreated 
localized disease, n = 38 
Patient with CRPC, 
n = 43 
Age, y    
        Median (IQR) 69 (76-62) 66.5 (72-57) 73 (81-67) 
PSA, ng/mL    
        Median (IQR) 15 (71-7.65) 8.91 (12.25-5.40) 61 (367-23) 
Primary Gleason Score, n (%)    
        6 13 (16) 11 (29) 2 (5) 
        3+4 17 (21) 14 (37) 3 (7) 
        4+3 14 (17) 9 (24) 5 (12) 
        8-10 24 (30) 4 (10) 20 (46) 
        n/a 13 (16) 0 (0) 13 (30) 
Prior therapy, n (%)    
        No treatment 38 (47) 38 (100) 0 (0) 
        Systemic therapy 43 (53) 0 (0) 43 (100) 
Metastasis, n (%)    
        No 41 (51) 38 (100) 3 (7) 
       Yes 40 (49) 0 (0) 40 (93) 
CK+/VIM-/CD45- cell    
       Detectable patient number (%) 49 (60) 18 (47) 31 (72) 
       Cell number, median (IQR) 1 (4-0) 0 (2-0) 2 (9-0) 
CK+/VIM+/CD45- cell    
       Detectable patient number (%) 37 (46) 7 (18) 30 (70) 
       Cell number, median (IQR) 0 (2-0) 0 (0-0) 2 (4-0) 
CK-/VIM+/CD45- cell    
       Detectable patient number (%) 59 (73) 21 (55) 38 (88) 
       Cell number, median (IQR) 2 (6-0) 1 (4-0) 4 (8-2) 
Total CTC    
       Detectable patient number (%) 73 (90) 30 (79) 43 (100) 
       Cell number, median (IQR) 6 (14-3) 3 (6-1) 11 (19-7) 
IQR: interquartile range (Q75-Q25%); CRPC: castration-resistant prostate cancer; CK: cytokeratin; VIM: 
Vimentin. 
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Table 2.  Predictors for survival in progressive mCRPC patients at baseline 
 HR (95% CI) LR χ² test adjusted p* 
Age (y) 0.994 (0.923-1.070) 0.02 0.875 
PSA (ng/mL) 1.0006 (1.0003-1.0009) 9.84 0.015 
GS 1.145 (0.598-2.193) 0.17 0.804 
ALP (U/L) 1.003 (1.001-1.004) 8.77 0.015 
LDH (U/L) 1.003 (1.001-1.006) 6.28 0.040 
Epithelial CTCs (n) 1.005 (0.972-1.039) 0.08 0.847 
EMTing CTCs (n) 1.066 (0.948-1.198) 0.95 0.477 
Mesenchymal CTCs (n) 1.046 (1.008-1.086) 3.78 0.135 
Total CK+ CTCs (n) 1.008 (0.979-1.038) 0.24 0.804 
Total VIM+ CTCs (n) 1.032 (1.003-1.062) 3.21 0.158 
Total CTCs (n) 1.014 (0.995-1.035) 1.58 0.338 
BigNeg cells (n) 0.849 (0.628-1.146) 1.93 0.306 
CMS  1.282 (1.097-1.499) 8.59 0.015 
* Benjamini & Hochberg' adjustment (15) 
HR: hazard ratio; GS: Gleason Score of the primary tumor; CI: confidential interval; ALP: alkaline phosphatase; 
LDH: lactate dehydrogenase; BigNeg cells: CK-/VIM-/CD45- cells with big nuclei; CMS: Combined 







Fig. 1. Representative images for different populations of detected cells in prostate cancer 
patients and five rounds of FISH in a CTC. (A) Immunofluorescence image for three types of 
circulating cells. Top row: One CK+/VIM-/CD45- cell (arrowed) adjacent to one CD45+ 
lymphocyte. Middle row: Two CK+/VIM+/CD45- cells (arrowed) adjacent to one CD45+ 
lymphocyte. Bottom row: Two CK-/VIM+/CD45- cells (arrowed) adjacent to one CD45+ 
lymphocyte. (B) Five rounds of FISH on one CK-/VIM+/CD45- CTC post-immunostaining. 
First round of FISH: AR (red) and 6q16 (green). Second round of FISH for ERG 
rearrangement: RP11-476D17 (red) and RP11-95I21 (green). Third round of FISH: C-MYC 
(red) and NKX3.1 (green). Fourth round of FISH: RB1 (red) and PTEN (green). Fifth round of 
FISH: CCND1 (red) and 16q22.1 (green). FISH signals are indicated by arrows.  
 
Fig. 2. The correlation of CTC count with clinical features. (A) Association of PSA with 
epithelial CTCs, EMTing CTCs, mesenchymal CTCs, total CK+ CTCs, total VIM+ CTCs 
and total CTCs. The numbers of all types of CTCs were higher in patients with higher GS of 
primary tumor (B), patients with untreated high-risk localized disease (C), and patients with 
metastases (D). (E) ROC analysis of the efficiencies of serum PSA level (AUC = 0.823) and 
CRS (AUC = 0.921) in discriminating metastatic prostate cancer patients from those without 
metastasis are shown in crosses and black dots respectively. An AUC equal to 1 suggests 





Fig. 3. Representative immunofluorescence/FISH images and nuclear size of BigNeg cells. 
(A) An example of a BigNeg cell (arrowed) with a big and bright Nucleus and negative 
signals for CD45, CK and VIM and two adjacent CD45+/VIM+ lymphocytes. (B) BigNeg 
cells (arrowed) could be easily screened and identified under low resolution image based on 
nucleus size alone. (C) FISH analysis by probes of AR (red) and 6q16 (green) showed 
polyploidy of the BigNeg cell (arrowed) and an adjacent diploid lymphocyte (arrow-head) 
which was CD45 positive on previous immunostaining. (D) Comparison of nucleus diameter 
between BigNeg cells and lymphocytes where no size overlap was observed. 
 
Fig. 4. BigNeg cell count was associated with survival and their megakaryocyte nature was 
confirmed by immunofluorescence. (A) Kaplan-Meier curve for overall survival showed 
progressive prostate cancer patients with less than three BigNeg cells had significantly 
shorter survival rates (p = 0.032). (B) Kaplan-Meier curve for overall survival showed 
progressive prostate cancer patients with CMS ≥ 2.0 had even poorer survival (p = 0.0003). 
(C) PMA-treated K562 cell lines were positive for CD34 and CD41 staining with various 
patterns:  strong CD41 but weak CD34 (top row), similar signal strength of CD41 and CD34 
(middle row), and strong CD34 but negative CD41 (bottom row). Cells with obvious CD41 
signals were larger than those without or with very weak CD41 staining. (D) Top and middle 
row: BigNeg cells were positive for both CD41 and CD34, and signals of CD41 were 
relatively stronger. Bottom row: one BigNeg cell was positive for CD34 but not CD41. The 
adjacent CD45+ (image not shown) lymphocyte (with arrow-head) was negative for both 
CD34 and CD41. BigNeg cells positive for CD41 were relatively larger than those with no 
CD41 expression. 




